Trovagene Inc (TROV) 4.99 $TROV
Trovagene closes equity offering
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 10:55AM CST
TROV: 4.99 (-0.17)
Trovagene, Inc. Announces Closing of Public Offering of Common Stock
PR Newswire - Wed Feb 11, 9:12AM CST
Trovagene, Inc. (NASDAQ: TROV) today announced the closing of its previously announced underwritten public offering. The Company sold 5,111,110 shares of its common stock in the offering, which includes 666,666 shares that were issued upon the full exercise by the underwriters of their over-allotment option. The offering price was $4.50 per share and gross proceeds to Trovagene are approximately $23 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trovagene.
TROV: 4.99 (-0.17)
InsiderInsights.com Daily Round Up 2/10/15: ZIOP, WMS, R, MLNK
InsiderInsights - at Seeking Alpha - Wed Feb 11, 3:29AM CST
ZIOP: 9.64 (-0.35), TROV: 4.99 (-0.17), CRR: 40.35 (+2.73), SLG: 128.59 (-0.65), WMS: 25.03 (+0.36), MLNK: 3.78 (+0.04), RXN: 27.85 (+0.08), KTWO: 19.75 (+0.01), PANW: 135.27 (+2.26), YHOO: 44.42 (+0.50), WHR: 213.23 (+0.18), UA: 73.76 (-0.19), GILD: 101.90 (+1.10), R: 93.92 (+0.41), SIX: 45.11 (-0.05), DATA: 99.90 (+1.40), TW: 131.99 (-0.41), MA: 87.14 (-0.38), NVET: 9.66 (-0.18), IPGP: 87.26 (+0.07)
Trovagene, Inc. to Present at Leerink Global Healthcare Conference
PR Newswire - Tue Feb 10, 7:05AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the 2015 Leerink Global Healthcare Conference.
TROV: 4.99 (-0.17)
Senistivity of Trovagene HPV test with urine lower versus cervical samples
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 12:43PM CST
TROV: 4.99 (-0.17)
Clinical Results Demonstrate High Sensitivity of Trovagene's Urine-Based HPV Assay for the Detection of High Risk HPV and Pre-Cancerous Cervical Lesions
PR Newswire - Mon Feb 09, 7:05AM CST
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced the presentation of clinical results from the PREDICTORS 4 trial, which demonstrate high sensitivity for the Company's non-invasive, urine-based HPV assay when determining high-risk human papillomavirus (HPV) types and cervical lesions or cervical intraepithelial neoplasia (CIN) Grade 2/3. Jack Cuzick, Ph.D., Director, Wolfson Institute of Preventive Medicine and Head, Centre for Cancer Prevention at Queen Mary University of London, presented the study results at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) 2015 Congress in Sevilla, Spain.
TROV: 4.99 (-0.17)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 11:45AM CST
GSB: 3.15 (+0.11), ARCW: 6.62 (+0.23), CBM: 32.96 (+0.09), TROV: 4.99 (-0.17), HGSH: 3.05 (-0.13), RENT: 58.90 (+0.39), NKA: 1.68 (+0.13), EGAN: 3.78 (+0.08), BIOC: 1.41 (+0.22), CPPL: 28.18 (+0.39), DAC: 5.86 (-0.01), MXWL: 6.47 (+0.07), XLS: 24.15 (+0.04), PLUS: 80.17 (-0.21), EARS: 5.88 (-0.01), P: 15.44 (+0.45), ATV: 1.17 (-0.08), YELP: 47.53 (-0.10), TWTR: 48.50 (+0.55), CTRL: 13.39 (+0.10)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 8:12AM CST
HRS: 77.73 (+0.42), GPRO: 45.27 (-0.02), NLST: 1.86 (unch), TROV: 4.99 (-0.17), AU: 12.33 (+0.36), NMM: 12.37 (+0.24), EOX: 1.15 (unch), NBG: 1.61 (+0.18), ONTY: 1.57 (unch), ATVI: 23.11 (+0.17), PBR: 6.98 (+0.44), XLS: 24.15 (+0.04), MHR: 2.62 (+0.11), CIG: 4.29 (+0.10), PWE: 2.45 (+0.02), LNKD: 269.00 (+1.83), GDP: 3.58 (+0.29), SFY: 2.91 (+0.26), P: 15.44 (+0.45), TPX: 55.62 (+1.71), EXPE: 89.49 (-0.08), OHRP: 7.38 (-0.30), TWTR: 48.50 (+0.55), YELP: 47.53 (-0.10)
Trovagene, Inc. Announces Pricing of Public Offering of Common Stock
PR Newswire - Fri Feb 06, 7:27AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced the pricing of an underwritten public offering of 4,444,444 shares of its common stock. The gross proceeds to Trovagene from this offering are expected to be approximately $20 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trovagene. The offering is expected to close on or about February 11, 2015, subject to customary closing conditions. Trovagene has also granted to the underwriters a 30-day option to purchase from it up to an additional 666,666 shares of its common stock.
TROV: 4.99 (-0.17)
Trovagene off on equity offering
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 6:48AM CST
TROV: 4.99 (-0.17)
Trovagene, Inc. Announces Public Offering of Common Stock
PR Newswire - Thu Feb 05, 3:09PM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that it is offering to sell shares of its common stock in an underwritten public offering. The offering is expected to price on or about Friday, February 6, 2015.
TROV: 4.99 (-0.17)
3 Biotech Stocks Under $10 in Breakout Territory: TrovaGene and More
at The Street - Thu Jan 29, 12:06PM CST
These under-$10 biotech stocks are within range of triggering breakout trades.
TROV: 4.99 (-0.17), APRI: 1.84 (-0.08), THLD: 4.03 (+0.21)
TrovaGene Partners with Leading Cancer Research Institutes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 26, 11:00AM CST
TrovaGene Inc. (TROV) recently announced a number of collaborations with eminent research institutes around the world.
TROV: 4.99 (-0.17), NLNK: 38.84 (+1.51), AMGN: 153.48 (+0.30), CELG: 115.88 (+0.16)
Trovagene's Chief Scientific Officer to Present Precision Cancer Monitoring (SM) Platform Overview at the Personalized Medicine World Conference
PR Newswire - Mon Jan 26, 7:35AM CST
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Chief Scientific Officer, Mark Erlander, Ph.D., will present an overview of the Company's Precision Cancer MonitoringSM platform during the 2015 Personalized Medicine World Conference in Silicon Valley. Erlander's presentation, titled "Quantitative Detection of Cancer Mutations in Liquid Biopsy Samples," will be delivered today, during Track 1 at 11:15 a.m. PST.
TROV: 4.99 (-0.17)
Seeking Alpha's Biotech Weekly: Salix Sale Murmurs, A Very Active CHMP, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Jan 23, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
CRIS: 3.23 (+0.25), NAVB: 1.60 (unch), TROV: 4.99 (-0.17), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), ABBV: 58.05 (+1.00), ARIA: 7.35 (+0.45), ARNA: 4.55 (+0.02), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Trovagene expands clinical collaboration with Czech firm
Seeking Alpha - at Seeking Alpha - Wed Jan 21, 8:27AM CST
TROV: 4.99 (-0.17)
Trovagene Expands Collaboration with Genomac to Demonstrate Clinical Utility in Lung and Colorectal Cancer Treatment Monitoring
PR Newswire Europe - Wed Jan 21, 2:02AM CST
-- Prospective clinical studies to evaluate Trovagene's Precision Cancer Monitoring platform to determine the emergence of resistance mutations using circulating tumor DNA
TROV: 4.99 (-0.17)
Clinical Study Results Presented at the 2015 Gastrointestinal Cancer Symposium Support Utility of Trovagene's Precision Cancer Monitoring Platform in Colorectal and Pancreatic Cancer Patients
PR Newswire - Tue Jan 20, 7:15AM CST
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced the presentation of results from two clinical studies at the 2015 Gastrointestinal Cancer Symposium (also known as ASCO GI) held in San Francisco, CA. Results demonstrate the ability of the Company's Precision Cancer MonitoringSM platform to detect and quantitate KRAS mutations at diagnosis and longitudinally in cell-free DNA (cfDNA) obtained from colorectal and pancreatic cancer patients.
TROV: 4.99 (-0.17)
Trovagene Collaborates with UC San Diego Moores Cancer Center to Demonstrate Clinical Utility of Detecting and Monitoring EGFR Mutations in Lung Cancer Patients
PR Newswire - Mon Jan 12, 7:35AM CST
Trovagene, Inc. (NASDAQ: TROV), today announced that it has entered into a clinical collaboration with University of California, San Diego Moores Cancer Center to determine the utility of detecting and monitoring EGFR mutations, using its Precision Cancer MonitoringSM platform. This large-scale study expands on the Company's clinical programs in lung cancer at Memorial Sloan Kettering Cancer Center and City of Hope Medical Center. Lung cancer is the leading cause of cancer mortality worldwide, and Trovagene is focused on providing an improved solution for the detection and monitoring of EGFR mutations in lung cancer patients.
TROV: 4.99 (-0.17)
Trovagene closes equity offering
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 10:55AM CST
TROV: 4.99 (-0.17)
Trovagene, Inc. Announces Closing of Public Offering of Common Stock
PR Newswire - Wed Feb 11, 9:12AM CST
Trovagene, Inc. (NASDAQ: TROV) today announced the closing of its previously announced underwritten public offering. The Company sold 5,111,110 shares of its common stock in the offering, which includes 666,666 shares that were issued upon the full exercise by the underwriters of their over-allotment option. The offering price was $4.50 per share and gross proceeds to Trovagene are approximately $23 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trovagene.
TROV: 4.99 (-0.17)
InsiderInsights.com Daily Round Up 2/10/15: ZIOP, WMS, R, MLNK
InsiderInsights - at Seeking Alpha - Wed Feb 11, 3:29AM CST
ZIOP: 9.64 (-0.35), TROV: 4.99 (-0.17), CRR: 40.35 (+2.73), SLG: 128.59 (-0.65), WMS: 25.03 (+0.36), MLNK: 3.78 (+0.04), RXN: 27.85 (+0.08), KTWO: 19.75 (+0.01), PANW: 135.27 (+2.26), YHOO: 44.42 (+0.50), WHR: 213.23 (+0.18), UA: 73.76 (-0.19), GILD: 101.90 (+1.10), R: 93.92 (+0.41), SIX: 45.11 (-0.05), DATA: 99.90 (+1.40), TW: 131.99 (-0.41), MA: 87.14 (-0.38), NVET: 9.66 (-0.18), IPGP: 87.26 (+0.07)
Trovagene, Inc. to Present at Leerink Global Healthcare Conference
PR Newswire - Tue Feb 10, 7:05AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the 2015 Leerink Global Healthcare Conference.
TROV: 4.99 (-0.17)
Senistivity of Trovagene HPV test with urine lower versus cervical samples
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 12:43PM CST
TROV: 4.99 (-0.17)
Clinical Results Demonstrate High Sensitivity of Trovagene's Urine-Based HPV Assay for the Detection of High Risk HPV and Pre-Cancerous Cervical Lesions
PR Newswire - Mon Feb 09, 7:05AM CST
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced the presentation of clinical results from the PREDICTORS 4 trial, which demonstrate high sensitivity for the Company's non-invasive, urine-based HPV assay when determining high-risk human papillomavirus (HPV) types and cervical lesions or cervical intraepithelial neoplasia (CIN) Grade 2/3. Jack Cuzick, Ph.D., Director, Wolfson Institute of Preventive Medicine and Head, Centre for Cancer Prevention at Queen Mary University of London, presented the study results at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) 2015 Congress in Sevilla, Spain.
TROV: 4.99 (-0.17)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 11:45AM CST
GSB: 3.15 (+0.11), ARCW: 6.62 (+0.23), CBM: 32.96 (+0.09), TROV: 4.99 (-0.17), HGSH: 3.05 (-0.13), RENT: 58.90 (+0.39), NKA: 1.68 (+0.13), EGAN: 3.78 (+0.08), BIOC: 1.41 (+0.22), CPPL: 28.18 (+0.39), DAC: 5.86 (-0.01), MXWL: 6.47 (+0.07), XLS: 24.15 (+0.04), PLUS: 80.17 (-0.21), EARS: 5.88 (-0.01), P: 15.44 (+0.45), ATV: 1.17 (-0.08), YELP: 47.53 (-0.10), TWTR: 48.50 (+0.55), CTRL: 13.39 (+0.10)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 8:12AM CST
HRS: 77.73 (+0.42), GPRO: 45.27 (-0.02), NLST: 1.86 (unch), TROV: 4.99 (-0.17), AU: 12.33 (+0.36), NMM: 12.37 (+0.24), EOX: 1.15 (unch), NBG: 1.61 (+0.18), ONTY: 1.57 (unch), ATVI: 23.11 (+0.17), PBR: 6.98 (+0.44), XLS: 24.15 (+0.04), MHR: 2.62 (+0.11), CIG: 4.29 (+0.10), PWE: 2.45 (+0.02), LNKD: 269.00 (+1.83), GDP: 3.58 (+0.29), SFY: 2.91 (+0.26), P: 15.44 (+0.45), TPX: 55.62 (+1.71), EXPE: 89.49 (-0.08), OHRP: 7.38 (-0.30), TWTR: 48.50 (+0.55), YELP: 47.53 (-0.10)
Trovagene, Inc. Announces Pricing of Public Offering of Common Stock
PR Newswire - Fri Feb 06, 7:27AM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced the pricing of an underwritten public offering of 4,444,444 shares of its common stock. The gross proceeds to Trovagene from this offering are expected to be approximately $20 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trovagene. The offering is expected to close on or about February 11, 2015, subject to customary closing conditions. Trovagene has also granted to the underwriters a 30-day option to purchase from it up to an additional 666,666 shares of its common stock.
TROV: 4.99 (-0.17)
Trovagene off on equity offering
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 6:48AM CST
TROV: 4.99 (-0.17)
Trovagene, Inc. Announces Public Offering of Common Stock
PR Newswire - Thu Feb 05, 3:09PM CST
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that it is offering to sell shares of its common stock in an underwritten public offering. The offering is expected to price on or about Friday, February 6, 2015.
TROV: 4.99 (-0.17)
3 Biotech Stocks Under $10 in Breakout Territory: TrovaGene and More
at The Street - Thu Jan 29, 12:06PM CST
These under-$10 biotech stocks are within range of triggering breakout trades.
TROV: 4.99 (-0.17), APRI: 1.84 (-0.08), THLD: 4.03 (+0.21)
TrovaGene Partners with Leading Cancer Research Institutes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 26, 11:00AM CST
TrovaGene Inc. (TROV) recently announced a number of collaborations with eminent research institutes around the world.
TROV: 4.99 (-0.17), NLNK: 38.84 (+1.51), AMGN: 153.48 (+0.30), CELG: 115.88 (+0.16)
Trovagene's Chief Scientific Officer to Present Precision Cancer Monitoring (SM) Platform Overview at the Personalized Medicine World Conference
PR Newswire - Mon Jan 26, 7:35AM CST
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Chief Scientific Officer, Mark Erlander, Ph.D., will present an overview of the Company's Precision Cancer MonitoringSM platform during the 2015 Personalized Medicine World Conference in Silicon Valley. Erlander's presentation, titled "Quantitative Detection of Cancer Mutations in Liquid Biopsy Samples," will be delivered today, during Track 1 at 11:15 a.m. PST.
TROV: 4.99 (-0.17)
Seeking Alpha's Biotech Weekly: Salix Sale Murmurs, A Very Active CHMP, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Jan 23, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
CRIS: 3.23 (+0.25), NAVB: 1.60 (unch), TROV: 4.99 (-0.17), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), ABBV: 58.05 (+1.00), ARIA: 7.35 (+0.45), ARNA: 4.55 (+0.02), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
Trovagene expands clinical collaboration with Czech firm
Seeking Alpha - at Seeking Alpha - Wed Jan 21, 8:27AM CST
TROV: 4.99 (-0.17)
Trovagene Expands Collaboration with Genomac to Demonstrate Clinical Utility in Lung and Colorectal Cancer Treatment Monitoring
PR Newswire Europe - Wed Jan 21, 2:02AM CST
-- Prospective clinical studies to evaluate Trovagene's Precision Cancer Monitoring platform to determine the emergence of resistance mutations using circulating tumor DNA
TROV: 4.99 (-0.17)
Clinical Study Results Presented at the 2015 Gastrointestinal Cancer Symposium Support Utility of Trovagene's Precision Cancer Monitoring Platform in Colorectal and Pancreatic Cancer Patients
PR Newswire - Tue Jan 20, 7:15AM CST
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced the presentation of results from two clinical studies at the 2015 Gastrointestinal Cancer Symposium (also known as ASCO GI) held in San Francisco, CA. Results demonstrate the ability of the Company's Precision Cancer MonitoringSM platform to detect and quantitate KRAS mutations at diagnosis and longitudinally in cell-free DNA (cfDNA) obtained from colorectal and pancreatic cancer patients.
TROV: 4.99 (-0.17)
Trovagene Collaborates with UC San Diego Moores Cancer Center to Demonstrate Clinical Utility of Detecting and Monitoring EGFR Mutations in Lung Cancer Patients
PR Newswire - Mon Jan 12, 7:35AM CST
Trovagene, Inc. (NASDAQ: TROV), today announced that it has entered into a clinical collaboration with University of California, San Diego Moores Cancer Center to determine the utility of detecting and monitoring EGFR mutations, using its Precision Cancer MonitoringSM platform. This large-scale study expands on the Company's clinical programs in lung cancer at Memorial Sloan Kettering Cancer Center and City of Hope Medical Center. Lung cancer is the leading cause of cancer mortality worldwide, and Trovagene is focused on providing an improved solution for the detection and monitoring of EGFR mutations in lung cancer patients.
TROV: 4.99 (-0.17)
